Novo Nordisk's Pipeline Momentum Meets a Market That Won't Budge

Novo Nordisk reported oral Wegovy, Ozempic and CagriSema data, but shares sit 25% lower in 2026 as the FDA extended its Denecimig review.

Fresh clinical evidence across three fronts is giving Novo Nordisk plenty to talk about, yet the Danish drugmaker's equity continues to languish near its yearly lows. Shares closed Friday at EUR 33.06, leaving the stock down 25% since the start of 2026 and the company valued at EUR 146.62 billion. The disconnect says as much about shifting growth expectations as it does about the science itself.

Oral Wegovy Delivers in the Real World

At the European Association for the Study of Diabetes conference, Novo Nordisk unveiled data from the OCTANE trial on Wednesday. Adults who switched from injectable weight-loss treatments to the oral Wegovy pill shed an additional 4.1% of body weight on average after three months. Because the study tracked routine clinical practice rather than tightly controlled registration trials, the findings offer a window into how the tablet performs outside ideal conditions. Oral GLP-1 delivery carries strategic weight for the company, which aims to expand global manufacturing capacity for these treatments tenfold.

Ozempic Edges Out Tirzepatide on Heart Risk

A day earlier, the company presented a large registry analysis covering 636,525 adults with type 2 diabetes. Patients on the 2-milligram Ozempic dose showed a statistically significant 6% lower risk of major cardiovascular events than those switched to rival therapy tirzepatide. That result sharpens Ozempic's competitive profile in a market where both manufacturers are fighting hard for dominance in metabolic disease — and where cardiovascular outcomes data often determine whether insurers agree to reimburse.

CagriSema Posts Strong Phase 3 Numbers

In the obesity pipeline, CagriSema added its own supporting evidence. The REIMAGINE 5 study recorded an estimated average weight reduction of 12.4% with CagriSema versus 9.1% for tirzepatide, while the REDEFINE 9 comparison trial showed a 21.0% weight loss against placebo. Those phase 3 readouts underline how quickly the scientific bar is rising in the race for next-generation obesity therapies.

FDA Review of Denecimig Slips

Not everything went smoothly on the regulatory side. Reuters reported that the US Food and Drug Administration extended its review of Denecimig for hemophilia A because remediation work at a production site remains ongoing. Novo Nordisk said the delay will not affect its financial outlook for 2026, and it still targets a US launch in the first half of 2027, subject to approval.

Buybacks and Licensing Deals Keep Capital Moving

Even with the share price under pressure, management is pressing ahead with shareholder returns. According to company disclosures dated September 28, the ongoing repurchase program had bought back 35,379,179 B-shares as of September 25, for a total transaction volume of DKK 9,939,842,031. Such moves signal robust cash generation and provide some support for the stock at current levels.

On the technology side, Novo Nordisk is leaning on outside partnerships. Media reports indicated a worldwide exclusive license and collaboration agreement with Nanexa on September 25 covering the PharmaShell technology, spanning up to five development programs for selected peptide drugs. Nanexa stands to receive up to EUR 1.165 billion, of which EUR 615 million covers upfront, development, and approval milestones, plus low single-digit percentage royalties.

A separate deal with Jiangsu Hengrui Pharmaceuticals added HRS-1596 to the pipeline for development and commercialization outside Greater China, with a USD 300 million upfront payment and a potential total value of up to USD 2.6 billion including milestones and royalties.

A Stock Still Searching for Traction

The medical data alone has not reversed sentiment. Roughly two weeks ago, skepticism over management's long-term growth targets triggered a noticeable pullback. On top of that, CFRA analyst Wan Nurhayati downgraded the US depositary receipts on September 22 from "Hold" to "Sell" with a USD 38 price target. For investors, the question now is whether external assets, formulation advances, and clinical wins can offset competitive pressure in Novo Nordisk's core segments — and whether the market will eventually reward a company that, despite regulatory setbacks, is holding firmly to its strategic course.